Andrew Davies, MRCP, PhD from University of Southampton, Southampton, UK gives an overview of the subjects discussed during the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Subjects include PI 3-Kinase and BTK inhibition, as well as looking into high risk features of chronic lymphocytic leukemia (CLL) and non-hodgkin lymphoma (NHL). Dr Davies also discusses how practitioners are moving away from clinical parameters such as the follicular lymphoma international prognostic index (FLIPI), and now identifying high-risk patients using a M7-FLIPI. This is a combination of FLIPI performance status and the mutation status of 7 genes, which is a much better descriptor than the FLIPI score according to Dr Davies.
Moving away from the follicular lymphoma international prognostic index
